Trafalgar International (GCAN) Income from Continuing Operations (2017 - 2026)
Greater Cannabis Company (GCAN) posted quarterly Income from Continuing Operations of 33376.0 for Q1 2026, up 67.76% year-over-year from 19895.55 in Q1 2025, and down 109.88% quarter-over-quarter from 337757.0 in Q4 2025.
Trafalgar International (GCAN) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Greater Cannabis Company's Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 33376.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 67.76% year-over-year to 33376.0; the TTM figure through Mar 2026 stood at 122571.0 (up 48.49% YoY), while the FY2025 annual figure was 331612.0, down 85.22% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 33376.0, down from 337757.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 337757.0 in Q4 2025, with the low at 390853.0 in Q2 2025.
- The 5-year median for Income from Continuing Operations is 46165.0 (2024), against an average of 56105.47.
- Peak annual rise in Income from Continuing Operations reached 879.18% in 2025, while the deepest fall reached 770.17% in 2025.
- Greater Cannabis Company's Income from Continuing Operations stood at 47401.0 in 2022, then rose by 1.14% to 46861.0 in 2023, then increased by 7.5% to 43348.0 in 2024, then surged by 879.18% to 337757.0 in 2025, then plunged by 109.88% to 33376.0 in 2026.
- Business Quant data shows GCAN's Income from Continuing Operations at 33376.0 in Q1 2026, 337757.0 in Q4 2025, and 36099.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Trafalgar International | 236,233.75 | 236,233.75 | - | -33,376.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33,376.00 |
| Dec 31, 2025 | 337,757.00 |
| Sep 30, 2025 | -36,099.00 |
| Jun 30, 2025 | -390,853.00 |
| Mar 31, 2025 | -103,511.00 |
| Dec 31, 2024 | -43,348.00 |
| Sep 30, 2024 | -46,165.00 |
| Jun 30, 2024 | -44,917.00 |
| Mar 31, 2024 | -44,611.00 |
| Dec 31, 2023 | -46,861.00 |
| Sep 30, 2023 | -53,430.00 |
| Jun 30, 2023 | -45,043.00 |
| Mar 31, 2023 | -43,068.00 |
| Dec 31, 2022 | -47,401.00 |
| Sep 30, 2022 | -102,776.00 |
| Jun 30, 2022 | -62,405.00 |
| Mar 31, 2022 | -147,686.00 |
| Dec 31, 2021 | -196,331.00 |
| Sep 30, 2021 | -252,278.00 |
| Jun 30, 2021 | -38,964.00 |